Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J E Kolitz

Showing results (11-20 of 36) with videos related to

Pageof 4
Sort By:
Cancer Immunology, Immunotherapy : CII|January 1, 1989
A phase-II study of low-dose cyclophosphamide and recombinant human interleukin-2 in metastatic renal cell carcinoma and malignant melanomaA Lindemann, K Höffken, R E Schmidt, et al.
Clinical Immunology and Immunopathology|August 1, 1987
T-cell activation defect in common variable immunodeficiency: restoration by phorbol myristate acetate (PMA) or allogeneic macrophagesW Fiedler, K W Sykora, K Welte, et al.
Journal of Biological Response Modifiers|October 1, 1988
Phase I trial of recombinant interleukin-2 and cyclophosphamide: augmentation of cellular immunity and T-cell mitogenic response with long-term administration of rIL-2J E Kolitz, G Y Wong, K Welte, et al.
Seminars in Oncology|June 1, 1992
A phase II pilot trial of high-dose hydroxyurea in chronic myelogenous leukemiaJ E Kolitz, S J Kempin, A Schluger, et al.
Experimental Cell Biology|January 1, 1988
Anti-tumor efficacy of interleukin-2-activated killer cells in human neuroblastoma ex vivoJ Atzpodien, S C Gulati, J H Kwon, et al.
Journal of Biological Response Modifiers|August 1, 1987
Expansion of activated T-lymphocytes in patients treated with recombinant interleukin 2J E Kolitz, K Welte, G Y Wong, et al.
Investigational New Drugs|September 1, 1988
A phase I trial of intraperitoneal recombinant interleukin 2 in patients with ovarian carcinomaP B Chapman, J E Kolitz, T B Hakes, et al.
Leukemia Research|July 31, 2012
Pharmacokinetics of CPX-351; a nano-scale liposomal fixed molar ratio formulation of cytarabine:daunorubicin, in patients with advanced leukemiaE J Feldman, J E Kolitz, J M Trang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 16, 2001
Impact of therapy With chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011V A Morrison, K R Rai, B L Peterson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 12, 1999
Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphomaL D Piro, C A White, A J Grillo-López, et al.
Pageof 4

Showing results (11-20 of 36) with videos related to

Sort By:
Pageof 4
Cancer Immunology, Immunotherapy : CII|January 1, 1989
A phase-II study of low-dose cyclophosphamide and recombinant human interleukin-2 in metastatic renal cell carcinoma and malignant melanomaA Lindemann, K Höffken, R E Schmidt, et al.
Clinical Immunology and Immunopathology|August 1, 1987
T-cell activation defect in common variable immunodeficiency: restoration by phorbol myristate acetate (PMA) or allogeneic macrophagesW Fiedler, K W Sykora, K Welte, et al.
Journal of Biological Response Modifiers|October 1, 1988
Phase I trial of recombinant interleukin-2 and cyclophosphamide: augmentation of cellular immunity and T-cell mitogenic response with long-term administration of rIL-2J E Kolitz, G Y Wong, K Welte, et al.
Seminars in Oncology|June 1, 1992
A phase II pilot trial of high-dose hydroxyurea in chronic myelogenous leukemiaJ E Kolitz, S J Kempin, A Schluger, et al.
Experimental Cell Biology|January 1, 1988
Anti-tumor efficacy of interleukin-2-activated killer cells in human neuroblastoma ex vivoJ Atzpodien, S C Gulati, J H Kwon, et al.
Journal of Biological Response Modifiers|August 1, 1987
Expansion of activated T-lymphocytes in patients treated with recombinant interleukin 2J E Kolitz, K Welte, G Y Wong, et al.
Investigational New Drugs|September 1, 1988
A phase I trial of intraperitoneal recombinant interleukin 2 in patients with ovarian carcinomaP B Chapman, J E Kolitz, T B Hakes, et al.
Leukemia Research|July 31, 2012
Pharmacokinetics of CPX-351; a nano-scale liposomal fixed molar ratio formulation of cytarabine:daunorubicin, in patients with advanced leukemiaE J Feldman, J E Kolitz, J M Trang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 16, 2001
Impact of therapy With chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011V A Morrison, K R Rai, B L Peterson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 12, 1999
Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphomaL D Piro, C A White, A J Grillo-López, et al.
Pageof 4